NCT06417814 2026-03-02
TROPION-Lung15
AstraZeneca
Phase 3 Recruiting
Clinical Trials
10 trialsNCT06970639 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT05624996 2026-01-14
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT06670196 2025-12-05
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 3 Recruiting
NCT06350097 2025-11-17
TROPION-Lung14
AstraZeneca
Phase 3 Recruiting
NCT06829459 2025-04-08
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
NCT05261399 2025-01-10
SAFFRON
AstraZeneca
Phase 3 Recruiting
NCT06735391 2024-12-16
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
NCT06486142 2024-07-03
ERIS
Region Skane
Phase 3 Recruiting
NCT05382728 2024-01-30
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
TYK Medicines, Inc
Phase 3 Recruiting